Department of Drug Discovery and Development, Istituto Italiano di Tecnologia, Genova, Italy.
PLoS One. 2011;6(5):e18845. doi: 10.1371/journal.pone.0018845. Epub 2011 May 17.
The role of virtual ligand screening in modern drug discovery is to mine large chemical collections and to prioritize for experimental testing a comparatively small and diverse set of compounds with expected activity against a target. Several studies have pointed out that the performance of virtual ligand screening can be improved by taking into account receptor flexibility. Here, we systematically assess how multiple crystallographic receptor conformations, a powerful way of discretely representing protein plasticity, can be exploited in screening protocols to separate binders from non-binders. Our analyses encompass 36 targets of pharmaceutical relevance and are based on actual molecules with reported activity against those targets. The results suggest that an ensemble receptor-based protocol displays a stronger discriminating power between active and inactive molecules as compared to its standard single rigid receptor counterpart. Moreover, such a protocol can be engineered not only to enrich a higher number of active compounds, but also to enhance their chemical diversity. Finally, some clear indications can be gathered on how to select a subset of receptor conformations that is most likely to provide the best performance in a real life scenario.
虚拟配体筛选在现代药物发现中的作用是挖掘大型化学库,并优先对具有针对目标预期活性的相对较小且多样化的化合物组合进行实验测试。有几项研究指出,通过考虑受体的柔性,可以提高虚拟配体筛选的性能。在这里,我们系统地评估了多种晶体学受体构象(离散表示蛋白质可塑性的一种有效方法)如何可用于筛选方案,以将结合物与非结合物区分开来。我们的分析涵盖了 36 个具有药物相关性的靶标,并且基于针对这些靶标具有报道活性的实际分子。结果表明,与标准的单一刚性受体相比,基于受体的组合协议在区分活性和非活性分子方面具有更强的区分能力。此外,不仅可以设计这种协议来富集更多的活性化合物,还可以提高它们的化学多样性。最后,可以清楚地了解如何选择一组最有可能在实际情况下提供最佳性能的受体构象子集。